ClinicalTrials.gg
TerminatedNCT05265013Updated Nov 4, 2024

ASP-1929 Photoimmunotherapy Combined With Pembrolizumab in Patients With Recurrent Head and Neck Cancer, With or Without Metastases

A Phase 2 interventional study of ASP-1929 Photoimmunotherapy and pembrolizumab in Head and Neck Cancer, sponsored by Rakuten Medical, Inc.. Terminated at 5 sites in Taiwan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2024-11-04.

Primary conditionSquamous Cell Carcinoma of Head and NeckRegistry: Head and Neck NeoplasmsReclassifiedWhy we changed it
Registry
Head and Neck Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Squamous Cell Carcinoma of Head and Neck
Why
  1. The study's title name Squamous Cell Carcinoma of Head and Neck, a narrower term within Head and Neck Neoplasms.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Rakuten Medical, Inc. · Phase 2, Interventional, and Treatment

How we know · 7 judgments

Why this study was terminated
Business decision

From the registry’s dates

  • Primary completion was Nov 2023, 3 years ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Oct 2024.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 112 studies in Squamous Cell Carcinoma of Head and Neck with a site in Taiwan — 30 open to participants now, 47 under way, 15 of them phase 3. Squamous Cell Carcinoma of Head and Neck · Taiwan.

Enrollment
96th of 101
16 · median 205
Started
2022
with 6 others
Phase 2
28 of 112
3 open now
Registered
71st of 112
by date
Lead sponsor
3 of 112
Rakuten Medical, Inc.

Among the 112 studies in Squamous Cell Carcinoma of Head and Neck with a site in Taiwan, this one is the 96th largest by enrollment of the 101 interventional ones that give a count, is one of 7 that started in 2022, is one of 28 in phase 2, and was the 71st registered.

Squamous Cell Carcinoma of Head and Neck

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

30 of the 112 studies in Squamous Cell Carcinoma of Head and Neck with a site in Taiwan are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 112 studies in Squamous Cell Carcinoma of Head and Neck with a site in Taiwan, or all of them as a file.
02

Study summary

A Phase 2 Single-arm Study of ASP-1929 Photoimmunotherapy Combined With Pembrolizumab in Patients With Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck, With or Without Metastases, Not Amenable to Curative Local Treatment

Read the detailed description

A Single-arm Study of ASP-1929 Photoimmunotherapy Combined With Pembrolizumab.

Patients will receive the approved label dose of pembrolizumab, which is administered every 3 weeks on days 1 and 22 of each treatment cycle.

On Day 8 of each cycle, patients will receive ASP-1929 followed by illumination at accessible tumor sites using the investigational PIT690 Laser System on Day 9.

Each treatment cycle, which is driven by ASP-1929 PIT frequency of administration, will last 42 days. Patients will be treated with ASP-1929 PIT and pembrolizumab for up to 12 months with a maximum of 8 treatment cycles.

03

Conditions studied

  • Head and Neck Cancer

Browse trials for

Keywords

  • Rakuten Medical
  • ASP-1929
  • PIT
  • Photoimmunotherapy
  • HNC
  • HNSCC
  • Head and neck
  • pembrolizumab
04

In context

Squamous Cell Carcinoma of Head and Neck Reclassified

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

This study's enrollment of 16 is below the median of 48 across 1,657 interventional studies indexed under Squamous Cell Carcinoma of Head and Neck.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Lead sponsor

Rakuten Medical, Inc. is the lead sponsor of 7 studies on the registry; 1 is open to participants now.

Compared within Squamous Cell Carcinoma of Head and Neck, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Head and Neck Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provide written .
  2. Male or female ≥ 20 years of age at the time of signing informed consent.
  3. Have or cytologically confirmed and diagnosed locoregional recurrent or second primary squamous cell carcinoma of the head and neck, not amenable to curative local treatment (ie, surgery and radiation therapy) per treatment guidelines. Patients with distant are eligible.
  4. Have provided tissue for biomarker analysis from a fresh core or excisional . A newly obtained screening biopsy (prior to start of study treatment with no intervening anticancer treatment from time of biopsy collection to C1D1) is strongly preferred but an archival sample is acceptable provided it has been collected within ≤ 6 months of enrollment and no intervening anticancer treatment has occurred within that timeframe or upon agreement from the Sponsor.
  5. Disease progression after treatment with a platinum-containing regimen for recurrent (disease not amenable to curative treatment)/metastatic disease. Note: disease progression may occur at any time during or after a platinum-containing regimen (eg, carboplatin or cisplatin) which was administered in the recurrent/metastatic setting.

    Note: Patients who were ineligible or unable to receive platinum therapy may be eligible after failing or progressing after suitable alternative systemic therapy (eg, 5-FU, cetuximab).

  6. Anti- treatment naive.
  7. Completed prior curative radiation therapy for treatment of the head and neck region, unless, in the opinion of the investigator, the use of radiation therapy was or not recommended.
  8. At least one recurrent head and neck tumor that is both accessible for illumination (as assessed by investigator) and radiographically measurable by v1.1 as assessed by an independent central reviewer (ICR) and the investigator. Lesions located in a previously irradiated area are considered measurable if progression has been demonstrated.

    1. Accessible tumors may be superficial lesions that are amenable to superficial illumination, regional metastatic lesions such as accessible lymph nodes, or deeper tumors that may be illuminated interstitially using cylindrical diffusers.
    2. Tumors that require needle catheters to go through bone (except tumors inside paranasal sinuses), arteries, major veins, eye globes, dura, or brain (including perineural invasion extending to the skull base) are not suitable for PIT illumination.
  9. Combined positive score (CPS) ≥ 1 (as determined by a Taiwan Food and Drug Administration/TFDA approved test).
  10. (ECOG) performance status of 0 or 1 at the time of screening.
  11. ≥ 3 months based on investigator judgement.
  12. Adequate organ function laboratory values as described below (all screening labs should be performed ≤ 7 days of C1D1):

    1. Hematology: Adequate bone marrow function as shown by (ANC) ≥ 1.5 x 10\^9/L, ≥ 100 x 10\^9/L, (Hb) ≥ 9 g/dL. Transfusions and growth factors must not be used within 2 weeks prior to C1D1 to meet these requirements.
    2. Hepatic: Alkaline phosphatase (ALP) ≤ 2 times (ULN), (AST) and alanine aminotransferase (ALT) ≤ 3 times the upper limit of normal (≤ 5 times ULN for patients with liver metastases), and total serum ≤ 2 mg/dL (unless the patient has Gilbert's disease).
    3. Renal: estimated (GFR) ≥ 60 mL/min/1.73 m² to be calculated per the CKD-EPI equation below:

      GFR = 141 * min (Scr/κ,1)ᵅ * max(Scr/κ, 1)-¹.²⁰⁹ * 0.993ᵃᵍᵉ * 1.018 [if female] * 1.159 [if Black] Note: Scr is serum creatinine (mg/dL), κ is 0.7 for females and 0.9 for males, α is -0.329 for females and -0.411 for males, min indicates the minimum of Scr/κ or 1, and max indicates the maximum of Scr/κ or 1.

    4. Coagulation: (INR) or prothrombin time (PT) ≤ 1.5 times ULN, unless patient is receiving anticoagulant therapy as long as PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants.
  13. Female patients of must not be pregnant (confirmed by negative pregnancy test [urine or serum] at screening) or breastfeeding and must be willing to use 2 methods of highly effective or practice abstinence throughout the study and for 120 days after the last dose of study medication. Females of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year.
  14. Male patients must be sterile or agree to use an adequate method of contraception or practice abstinence starting with the first dose of study medication through 120 days after the last dose of study treatment.

Exclusion criteria

Exclusion Criteria:

Patients will be excluded if any of the following criteria apply:

Medical History

  1. Diagnosed and/or treated for an additional within 5 years prior to study C1D1, except for those with a negligible risk of or death (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer, or ductal carcinoma in situ). Patients with a history of other prior cancer with no evidence of disease may be eligible based on discussion with the medical monitor.
  2. Tumor invading a major blood vessel unless the vessel has been embolized or surgically ligated to prevent hemorrhage; must not have involvement of the common or internal carotid arteries defined as invasion, encasement, or direct contact (lack of a radiographically visible plane between the tumor and carotid artery). Decision to exclude may be determined either by a central reviewer or by the investigator.
  3. Tumors inappropriate for ASP-1929 PIT treatment, including those in the brain or dura, with perineural involvement at the skull base, CNS (Central nervous system) disease, or disease in the orbit (if the eye has been previously removed, consult with the medical monitor before excluding). Decision to exclude may be determined by a central reviewer or the investigator.
  4. Known or active central nervous system metastases and/or carcinomatous meningitis.
  5. Active disease that has required systemic treatment in past 2 years (ie, with use of disease modifying agents, , or drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment.

    Note: Patients with type I diabetes mellitus or hypothyroidism requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are not excluded.

  6. Evidence of interstitial lung disease or current active, non-infectious pneumonitis.
  7. Active infection requiring systemic therapies such as antibiotic, antifungal, or antiviral intervention which in the opinion of the Investigator precludes the patient from participating in the clinical trial.
  8. Prior allogeneic tissue/solid organ transplant.
  9. History of significant (≥ grade 3) infusion reactions to anti-EGFR (EGFR, epidermal growth factor receptor) antibodies.
  10. History of allergic reactions attributed to compounds of similar chemical or biologic composition to ASP-1929 or pembrolizumab.
  11. Known history of testing positive for (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness.
  12. Known infection or detection of active (eg, HBsAg positive), active (eg, RNA [qualitative]), or SARS-CoV-2 (qualitative).
  13. Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  14. Any other condition which, in the investigator's opinion, deems the patient an unsuitable candidate to receive pembrolizumab, ASP-1929, and/or be exposed to illumination, may affect the interpretation of the results, or may render the patient at high risk from treatment complications.

    Prior and Concomitant Procedures

  15. Major surgery or significant traumatic injury within 4 weeks prior to C1D1, or anticipation of the need for major surgery during the study.

    Note: If patient has had major surgery, they must have recovered adequately (as determined by the investigator) from the toxicity and/or complications before C1D1.

  16. Requiring future examinations or treatments within 4 weeks after an ASP-1929 PIT treatment cycle exposing the patient to high intensity light (eg, eye examinations, surgical procedures that are unrelated to the ASP-1929 PIT treatment, the disease under study, or the study overall).

    Prior and Concomitant Medications

  17. Prior receipt of anticancer treatment as follows:

    1. Prior systemic chemotherapy or targeted small molecule therapy or radiation therapy within 2 weeks of C1D1 or has not recovered (ie, ≤ Grade 1 or at baseline) from adverse events due to previously administered agent.
    2. Prior anticancer monoclonal antibody therapy or agent or intervention within 4 weeks of C1D1 or has not recovered (ie, ≤ Grade 1 or at baseline) from adverse events due to previously administered agent.
    3. Prior receipt of ASP-1929 at any time.
  18. Receiving chronic systemic steroid therapy (in doses exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 14 days prior to C1D1.
  19. Received a live, attenuated vaccine within 4 weeks before C1D1 or anticipation of receiving a live, attenuated vaccine during the study (based on known medical history).

    Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (eg, Flu-Mist®) are and are not allowed.

  20. Unwilling or unable to follow protocol requirements.
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    ASP-1929 Photoimmunotherapy Combined With Pembrolizumab

    Patients will receive the approved label dose of pembrolizumab, which is administered every 3 weeks on days 1 and 22 of each treatment cycle. On Day 8 of each cycle, patients will receive ASP-1929 followed by illumination at accessible tumor sites using the investigational PIT690 Laser System on Day 9. Each treatment cycle, which is driven by ASP-1929 PIT frequency of administration, will last 42 days. Patients will be treated with ASP-1929 PIT and pembrolizumab for up to 12 months with a maximum of 8 treatment cycles.

    Combination Product: ASP-1929 Photoimmunotherapy · Biological: pembrolizumab

Interventions

  • Combination productCetuximab sarotalocan sodiumStudies of Cetuximab sarotalocan sodiumCetuximab sarotalocan sodium pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    ASP-1929 640 mg/m\^2 IV infusion followed by illumination with light dose of 50 J/cm\^2 for superficial lesions and 100 J/cm for interstitial lesions within 24 +/- 4 hours after the end of ASP-1929 infusion

    Also known as: cetuximab sarotalocan, PIT690 Laser System

  • Biologicalpembrolizumab

    200 mg every three weeks on days 1 and 22 of each 6-week cycle, 30 minute IV infusion

    Also known as: Keytruda

07

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR-PIT)

    the proportion of patients with confirmed PIT-treated tumor response of complete response (CR) or partial response (PR) per RECIST 1.1, as assessed by central reviewer.

    Time frame: 24 months

Secondary outcomes

  1. Duration of Response, for PIT-treated lesions

    Duration of Response (DoR; Duration of Response is defined as the time from first response (CR or PR) to the time of disease progression (PD) of PIT-treated lesions per RECIST 1.1, as assessed by central reviewer.

    Time frame: 24 months

  2. Assess effects on tumor response, for PIT-treated lesions

    Disease Control Rate (complete response, CR + partial response, PR + stable disease, SD) for PIT-treated lesions per RECIST 1.1, as assessed by central reviewer.

    Time frame: 24 months

  3. Assess effects on tumor response, Confirmed ORR for all lesions

    For all lesions per RECIST 1.1, as assessed by central reviewer: • Confirmed ORR (CR or PR)

    Time frame: 24 months

  4. Assess effects on tumor response, Disease control rate for all lesions

    For all lesions per RECIST 1.1, as assessed by central reviewer: • Disease control rate (DCR)

    Time frame: 24 months

  5. Assess effects on tumor response, DoR for all lesions

    For all lesions per RECIST 1.1, as assessed by central reviewer: • DoR

    Time frame: 24 months

  6. Assess effects on survival, PFS

    Progression-free Survival (PFS)

    Time frame: 24 months

  7. Assess effects on survival, OS

    Overall Survival (OS)

    Time frame: 24 months

  8. Characterize safety and tolerability

    Proportion of treatment-emergent adverse events (TEAEs), treatment-related adverse events (TRAEs), serious adverse events (SAEs) by Common Terminology Criteria for Adverse Events (CTCAE) v5.0.

    Time frame: 24 months

  9. Assess effects on quality of life, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)

    Change from baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30). It has four-point scales for the first 28 items. The minimum value is 1 and maximum value is 4. Higher scores mean a worse outcome. Overall health was evaluated as a 7-point response scale as the other two questions in that scale. The minimum value is 1 and maximum value is 7. Higher scores mean a better outcome.

    Time frame: 12 months

  10. Assess effects on quality of life, EORTC head and neck specific module (EORTC QLQ H&N 35)

    Change from baseline in EORTC head and neck specific module (EORTC QLQ H\&N 35). It has 4-point scales for the first 30 items. The minimum value is 1 and maximum value is 4. It has 2-point scales for the last 5 items. The minimum value is 1 and maximum value is 2. For all items and scales, high scores indicate more problems.

    Time frame: 12 months

  11. Assess effects on quality of life, Functional Assessment of Cancer Therapy Head & Neck Cancer Symptom Index - 10 Item (FHNSI-10)

    Proportion of patients who achieve a clinically meaningful benefit in symptoms, as measured by a 5-point improvement in Functional Assessment of Cancer Therapy Head \& Neck Cancer Symptom Index - 10 Item (FHNSI-10) from baseline to measured best assessment. The minimum value is 0 and maximum value is 4. Higher scores mean a worse outcome.

    Time frame: 12 months

  12. Characterize population pharmacokinetics of ASP-1929, AUC₀-ₜ (AUC, area under the concentration-time curve)

    Area under the concentration-time curve from time 0 through the last measurable time point.

    Time frame: 12 months

  13. Characterize population pharmacokinetics of ASP-1929, AUC₀-₂₆

    Area under the concentration-time curve from time 0 until 26 hours after infusion initiation (just prior to light treatment).

    Time frame: 12 months

  14. Characterize population pharmacokinetics of ASP-1929, AUC₀-∞

    Area under the concentration-time curve from time 0 through the last measurable time point and extrapolated to infinity.

    Time frame: 12 months

  15. Characterize population pharmacokinetics of ASP-1929, AUCₐₗₗ

    Area under the concentration-time curve using all available data from 0 through 2 weeks post dose.

    Time frame: 12 months

  16. Characterize population pharmacokinetics of ASP-1929, Cₘₐₓ (maximum observed drug concentration)

    Maximum observed concentration.

    Time frame: 12 months

  17. Characterize population pharmacokinetics of ASP-1929, tₘₐₓ (time to maximal concentration)

    Time of maximum observed concentration.

    Time frame: 12 months

  18. Characterize population pharmacokinetics of ASP-1929, t₁/₂ (mean terminal elimination half-life)

    The observed terminal elimination half-life.

    Time frame: 12 months

  19. Characterize population pharmacokinetics of ASP-1929, CL (volume of serum cleared of drug per unit time)

    The volume of serum cleared of drug per unit time following IV dosing (ASP-1929 only).

    Time frame: 12 months

  20. Characterize population pharmacokinetics of ASP-1929, Vₛₛ (volume of distribution at steady state following intravenous administration)

    Volume of distribution following IV dosing (ASP-1929 only).

    Time frame: 12 months

  21. Characterize presence of anti-drug antibodies (ADA)

    Proportion of patients with anti-ASP-1929 antibodies.

    Time frame: 24 months

08

Study locations

5 sites
  • China Medical University Hospital
    Taichung, 40447, Taiwan
  • Taichung Veterans General Hospital
    Taichung, 40705, Taiwan
  • National Taiwan University Hospital
    Taipei, 10048, Taiwan
  • Taipei Veterans General Hospital
    Taipei, 11217, Taiwan
  • Chang Gung Memorial Hospital
    Taoyuan, 33305, Taiwan
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2022 to primary completion in Nov 2023, 19 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2022
First posted
Mar 3, 2022
StartActual
Apr 19, 2022
Primary completionActual
Nov 20, 2023
CompletionActual
Mar 29, 2024
Results delay requested
Oct 16, 2024
Last update
Nov 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05265013
Lead sponsor
Rakuten Medical, Inc.
Responsible party
Sponsor
First posted
Mar 3, 2022
Start date
Apr 19, 2022
Primary completion
Nov 20, 2023
Completion
Mar 29, 2024
Last update
Nov 4, 2024

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cetuximab sarotalocan sodium

Start the discussion